The severity of neurocognitive impairment

(Bentham Science Publishers) Neurocognitive impairment is frequently encountered in multiple sclerosis patients affecting between 40-65 percent of these individuals, irrespective of disease duration, severity of physical disability, and at both the earlier and later disease stages, with a tendency to worsen over time.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news

Related Links:

Publication date: Available online 20 October 2018Source: Journal of Clinical NeuroscienceAuthor(s): Aaron E. Miller, Xianhao Xu, Richard Macdonell, Steve Vucic, Philippe Truffinet, Myriam Benamor, Karthinathan Thangavelu, Mark S. FreedmanAbstractIn the phase 3 TOWER (NCT00751881) study, teriflunomide 14 mg significantly reduced annualized relapse rate (ARR) and risk of 12-week confirmed disability worsening (12-w CDW) vs placebo in patients with relapsing forms of MS (RMS). The TOWER population included an appreciable proportion of Asian patients. Reductions in ARR and 12-w CDW associated with teriflunomide 14 mg were...
Source: Journal of Clinical Neuroscience - Category: Neuroscience Source Type: research
Conclusions Physiotherapy interventions can be a safe and beneficial option for spasticity in people with multiple sclerosis. No firm conclusion can be drawn on overall spasticity. Further researches in different spasticity aspects are needed.
Source: American Journal of Physical Medicine and Rehabilitation - Category: Rehabilitation Tags: Original Research Articles Source Type: research
Authors: Adamczyk B, Koziarska D, Kasperczyk S, Adamczyk-Sowa M Abstract So far little has been known about antioxidant properties of immunomodulatory drugs. The aim of the study was to evaluate the antioxidant status in serum of relapsing-remitting multiple sclerosis (RRMS) patients treated with II-line immunomodulatory therapy compared to de novo diagnosed patients, subjects treated with interferon (IFN) beta and healthy controls. We analyzed the relationships depending on the gender, age, disease duration, the Expanded Disability Status Scale (EDSS), the Annualized Relapse Rate (ARR) and MRI lesions in patients ...
Source: Free Radical Research - Category: Research Tags: Free Radic Res Source Type: research
Publication date: Available online 16 October 2018Source: Neuroscience LettersAuthor(s): M. Ďurfinová, Ľ. Procházková, D. Petrleničová, Z. Bystrická, K. Orešanská, Ľ. Kuračka, B. Líška
Source: Neuroscience Letters - Category: Neuroscience Source Type: research
CONCLUSIONS: MS patients with ON as the first manifestation display both lower disability scores and reduced serum adipokine levels implying that adipocytokine production is associated with MS progression. Exact mechanisms of this association in MS patients with first episode ON need to be further studied. PMID: 30321074 [PubMed - as supplied by publisher]
Source: Immunological Investigations - Category: Allergy & Immunology Tags: Immunol Invest Source Type: research
ConclusionsThough originally designed to segment T2L, MIMoSA performs well for segmenting T1 black holes in patients with MS.
Source: NeuroImage: Clinical - Category: Radiology Source Type: research
ConclusionsThese findings highlight the intrusiveness of MS on intimacy and sexual functioning, particularly among men. Potential clinical implications and future directions are discussed.
Source: Quality of Life Research - Category: Health Management Source Type: research
This article summarises the Evidence Review Group ’s review of the company’s evidence submission for cladribine and the Appraisal Committee’s final decision. The final scope issued by the National Institute for Health and Care Excellence listed the following disease-modifying treatments as comparators: alemtuzumab, daclizumab, fingolimod and natalizumab. At the time of the company submission, a licence was anticipated for low-dose cladribine. The main clinical evidence (the CLARITY trial) in the company submission focused on the efficacy of low-dose cladribine vs. placebo. The CLARITY trial showed a stati...
Source: PharmacoEconomics - Category: Health Management Source Type: research
CONCLUSION: Recognition of the impacts of perceived stigma on various aspects of the patients' lives are necessary to find appropriate strategies to deal with stigma and its consequences. Training programs can improve the patients' skills for coping with stigma. Furthermore, programs aimed to upgrade public knowledge and reduce the negative attitudes toward the disease should be promoted. PMID: 30315555 [PubMed - in process]
Source: Acta Neurologica Taiwanica - Category: Neurology Tags: Acta Neurol Taiwan Source Type: research
Authors: Finkelstein J, Liu J Abstract Patients with multiple sclerosis (PwMS) were shown to greatly benefit from multipronged exercise interventions comprising aerobic, resistance and corrective therapeutic components which result in endurance and strength improvement and reduction of fatigue and spasticity. However, telerehabilitation support of multipronged exercise programs in PwMS with significant mobility impairment has received limited attention. It is not clear whether severely disabled PwMS can successfully operate a telerehabilitation system at home independently. The goal of this study was to design a te...
Source: Studies in Health Technology and Informatics - Category: Information Technology Tags: Stud Health Technol Inform Source Type: research
More News: Brain | Disability | International Medicine & Public Health | Multiple Sclerosis | Neurology | Neuroscience | Science